Mutation adjacent to the active site tyrosine can enhance DNA cleavage and cell killing by the TOPRIM Gly to Ser mutant of bacterial topoisomerase I

Nucleic Acids Research

Volumn 36, Issue 3, 2008, Pages 1017-1025

  Cheng, Bokun ^a   Sorokin, Elena P ^a   Tse Dinh, Yuk Ching ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; AMINO ACID; ANTIBIOTIC AGENT; DNA TOPOISOMERASE; GLYCINE; METHIONINE; MUTANT PROTEIN; SERINE; TYROSINE;

AMINO ACID SUBSTITUTION; ARTICLE; CELL KILLING; CONTROLLED STUDY; DNA CLEAVAGE; DNA SYNTHESIS INHIBITION; DRUG TARGETING; ENZYME ACTIVITY; MOLECULAR INTERACTION; MUTATIONAL ANALYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN MOTIF; YERSINIA PESTIS;

AMINO ACID MOTIFS; AMINO ACID SUBSTITUTION; BINDING SITES; DNA; DNA TOPOISOMERASES, TYPE I, BACTERIAL; ESCHERICHIA COLI; GLYCINE; MAGNESIUM; METHIONINE; MUTATION; PHENOTYPE; SERINE; SOS RESPONSE (GENETICS); TYROSINE; VALINE; YERSINIA PESTIS;

BACTERIA (MICROORGANISMS); ESCHERICHIA COLI; YERSINIA PESTIS;

EID: 39449084697     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkm1126     Document Type: Article

References (41)

1. Champoux,J.J. (2001) DNA topoisomerases: Structure, function, and mechanism. Annu. Rev. Biochem., 70, 369-413.
2. Corbett,K.D. and Berger,J.M. (2004) Structure, molecular mechanisms, and evolutionary relationships in DNA topoisomerases. Annu. Rev. Biophys. Biomol. Struct., 33, 95-118.
3. Forterre,P., Gribaldo,S., Gadelle,P. and Serre,M.C. (2007) Origin and evolution of DNA topoisomerases. Biochimie, 89, 427-446.
4. Wang,J.C. (2002) Cellular roles of DNA topoisomerases: A molecular perspective. Nat. Rev. Mol. Cell Biol., 3, 430-440.
5. Liu,L.F. (1989) DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58, 351-375.
6. Chen,A.Y. and Liu,L.F. (1994) DNA topoisomerases: Essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 34, 191-218.
7. Nitiss,J.L. (2002) DNA topoisomerases in cancer chemotherapy: Using enzymes to generate selective DNA damage. Curr. Opin. Investig. Drugs 3, 1512-1516.
8. Pommier,Y. (2006) Topoisomerase I inhibitors: Camptothecins and beyond. Nat. Rev. Cancer, 6, 789-802.
9. Giles,G.I. and Sharma,R.P. (2005) Topoisomerase enzymes as therapeutic targets for cancer chemotherapy. Med. Chem., 1, 383-394.
10. Drlica,K. and Malik,M. (2003) Fluoroquinolones: Action and resistance. Curr. Top. Med. Chem., 3, 249-282.
11. Zhu,Q., Pongpech,P. and DiGate,R.J. (2001) Type I topoisomerase activity is required for proper chromosomal segregation in Escherichia coli. Proc. Natl Acad. Sci. USA, 98, 9766-9771.
12. Cheng,B., Shukla,S., Vasunilashorn,S., Mukhopadhyay,S. and Tse-Dinh,Y.C. (2005) Bacterial cell killing mediated by topoisomerase I DNA cleavage activity. J. Biol. Chem., 280, 38489-38495.
13. Cheng,B., Liu,I. and Tse-Dinh,Y.C. (2007) Compounds with antibacterial activity that enhance DNA cleavage by bacterial DNA topoisomerase I. J. Antimicrob. Chemother., 59, 640-645.
14. Tse-Dinh,Y.C. (2007) Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases. Infect. Disord. Drug Targets, 7, 3-9.
15. Gupta,M., Zhu,C.X. and Tse-Dinh,Y.C. (1994) Mutations of vaccinia virus DNA topoisomerase I that stabilize the cleavage complex. J. Biol. Chem., 269, 573-578.
16. Heitman,J. and Model,P. (1991) SOS induction as an in vivo assay of enzyme-DNA interactions. Gene, 103, 1-9.
17. Khlebnikov,A., Datsenko,K.A., SkaugT., Wanner,B.L. and Keasling,J.D. (2001) Homogeneous expression of the P(BAD) promoter in Escherichia cob by constitutive expression of the low-affinity high-capacity AraE transporter. Microbiology, 147, 3241-3247.
18. Siegele,D.A. and Hu,J.C. (1997) Gene expression from plasmids containing the araBAD promoter at subsaturating inducer concentrations represents mixed populations. Proc. Natl Acad. Sci. USA, 94, 8168-8172.
19. Zhu,C.X. and Tse-Dinh,Y.C. (1999) Overexpression and purification of bacterial DNA topoisomerase I. Methods Mol. Biol., 94, 145-151.
20. Zhu,C.X. and Tse-Dinh,Y.C. (2000) The acidic triad conserved in type IA DNA topoisomerases is required for binding of mg(II) and subsequent conformational change. J. Biol. Chem., 275, 5318-5322.
21. Kirkegaard,K., Pflugfelder,G. and Wang,J.C. (1984) The cleavage of DNA by type-I DNA topoisomerases. Cold Spring Harb. Symp. Quant. Biol. 49, 411-419.
22. Cheng,B., Feng,I., Mulay,V., Gadgil,S. and Tse-Dinh,Y.C. (2004) Site-directed mutagenesis of residues involve in G strand DNA binding by Escherichia coli DNA topoisomerase I. J. Biol. Chem., 279, 39207-39213.
23. Zhu,C.X., Roche,C.J. and Tse-Dinh,Y.C. (1997) Effect of mg(II) binding on the structure and activity of Escherichia-coli DNA topoisomerase I. J. Biol. Chem., 272, 16206-16210.
24. Depew,R.E., Liu,L.F and M. Wang,J.C. (1978) Interaction between DNA and Escherichia coli protein omega. 'Formation of a complex between single-stranded DNA and omega protein. J. Biol. Chem., 253, 511-518.
25. Liu,L.F. and Wang,J.C. (1979) Interaction between DNA and Escherichia coli DNA topoisomerase I. formation of complexes between the protein and superhelical.and nonsuperhelical duplex DNAs. J. Biol. Chem., 254, 11082-11088.
26. Caron,P.R. (1999) Compendium of DNA topoisomerase sequences. Methods Mol. Biol., 94, 279-316.
27. Aravind,L., Leipe,D.D. and Koonin,E.V. (1998) Toprim-a conserved catalytio- domain in type IA and H topoisomerases, DnaG-type primases, OLD family nucleases and RecR proteins. Nucleic Acids Res., 26 4205-4213.
28. Pandey,V.N., Kaushik.N., Rege,N., Sarafianos,S.G., Yadav,P.N. and Modak,M.J. (1996) Role of methionine 184 of human immunodeficiency virus type-1 reverse transcriptase in the polymerase function-and fidelity of DNA synthesis. Biochemistry, 35, 2168-2179.
29. Wohlers.T.M. and Fridovich-Keil,J.L. (2000) Studies of the V94M-substituted human UDPgalactose-4-epimerase enzyme associated with generalized epimerase-deficiency galactosaemia. J. Inherit. Metab. Dis., 23, 713-729.
30. Tahiri-Alaoui,A., Gill,A.C., Disterer,P. and James,W. (2004) Methionine 129 variant of human prion protein oligomerizes more rapidly than the valine 129 variant: Implications for disease susceptibility to creutzfeldt-jakob disease. J. Biol. Chem., 279, 31390-31397.
31. Rice,L.B. (2006) Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin. Infect. Dis., 43(SuppL 2), S100-S105.
32. Alekshim,M.N. and Levy,S.B. (2006) Commensals upon us. Biochem. Pharmacol., 71, 893-900.
33. Dorman,S.E. and Chaisson,R.E. (2007) From magic bullets back to the magic mountain: The rise of extensively drug-resistant tuberculosis. Nat. Med., 13, 295-298.
34. Furuya,E.Y. and Lowy,F.D. (2006) Antimicrobial-resistant bacteria in the community setting. Nat. Rev. Microbiol., 4, 36-45.
35. Jain,A.N. (2004) Virtual screening in lead discovery and optimization. Curr. Opin.Drug Discov. Devel., 7, 396-403.
36. Kitchen,D.B., Decornez,H., Furr,J.R. and Bajorath,J. (2004) Docking and scoring in virtual screening for drug discovery; methods and applications. Nat. Rev. Drug Discov., 3, 935-949.
37. Stoermer,M.J. (2006, Current status of virtual screening as analysed by tirget class. Med. Chem., 2, 89-112.
38. Changela,A, DiGate,R.J. and Moneragon,A (2001) Crystal structure of a complex of a type IA DNA toppisomerase, with a single-stranded DNA molecule. Nature, 411, 1077-1081.
39. Perry,K. and Mondragon,A. (2004) Structure of a complex between E. coli DNA topoisomerase I and single-stranded DNA. Structure, 11, 1349-1358.
40. Changela,A. DiGate,R.J. and Mondragon,A. (2007), Structural studies of E. coli topoisomerase III-DNA complexes reveal a novel type IA topomerase-DNA conformational intermediate. J. Mol. Biol., 368 105-119.
41. Lima,C.D., Wang,J.C. and Mondragon,A. (1994) Three-dimenional structure of the 67K N-terminal fragment of E. coli DNA-topoisomerase I. Nature 367, 138-146.